MedTrace Logo

IBAT Inhibitor A4250 for Cholestatic Pruritus

NCT02360852 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-02-23

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability and influence on itching, bile acids and liver enzyme changes in patients with PBC (Primary Biliary Cirrhosis) treated with A4250

Conditions

  • Biliary Cirrhosis, Primary

Interventions

DRUG

A4250

A4250 once daily

Sponsors & Collaborators

  • Albireo

    collaborator INDUSTRY

  • Sahlgrenska University Hospital

    lead OTHER

Principal Investigators

  • Hanns-Ulrich Marschall, MD · Sahlgrenska Academy, Institute of Medicine,

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02360852 on ClinicalTrials.gov